Using a cell-based reporter gene assay, we screened a library of drugs in clinical use and identified the anthracycline chemotherapeutic agents doxorubicin and daunorubicin as potent inhibitors of hypoxia-inducible factor 1 (HIF-1)-mediated gene transcription. These drugs inhibited HIF-1 by blocking its binding to DNA. Daily administration of doxorubicin or daunorubicin potently inhibited the transcription of a HIF-1-dependent reporter gene as well as endogenous HIF-1 target genes encoding vascular endothelial growth factor, stromal-derived factor 1, and stem cell factor in tumor xenografts. CXCR4 ؉ /sca1 ؉ , VEGFR2 ؉ /CD34 ؉ , and VEGFR2 ؉ / CD117 ؉ bone-marrow derived cells were increased in the peripheral blood of SCID mice bearing prostate cancer xenografts but not in tumor-bearing mice treated for 5 days with doxorubicin or daunorubicin, which dramatically reduced tumor vascularization. These results provide a molecular basis for the antiangiogenic effect of anthracycline therapy and have important implications for refining the use of these drugs to treat human cancer more effectively.
I
ntratumoral hypoxia is a common finding in human cancers and is associated with increased risk of tumor invasion, metastasis, and patient mortality (1) . A principal mechanism by which reduced O 2 availability promotes the lethal cancer phenotype is through induction of hypoxia-inducible factor 1 (HIF-1), which controls the expression of genes encoding proteins that play key roles in many aspects of cancer biology, including immortalization, stem cell maintenance, autocrine growth, angiogenesis, metabolic reprogramming, invasion, metastasis, and treatment resistance (2) . For example, HIF-1 activates transcription of the human VEGF gene, which encodes vascular endothelial growth factor (3) . HIF-1 gain-of-function or loss-offunction in human cancer cells has been shown to increase or decrease, respectively, VEGF expression and tumor vascularization (1, 2) . HIF-1 also activates transcription of genes encoding glucose transporter GLUT1 and hexokinases HK1 and HK2, which are required for the high level of glucose uptake and phosphorylation that is observed in metastatic cancer cells, and pyruvate dehydrogenase kinase 1 (PDK1), which shunts pyruvate away from the mitochondria, thereby increasing lactate production (1, 2) .
HIF-1 is a heterodimer consisting of HIF-1␣ (or HIF-2␣) and HIF-1␤ subunits (4) . The levels of HIF-1␣ increase dramatically as cellular O 2 concentration decreases because of decreased proteasomal degradation in hypoxic cells (5) . In well-oxygenated cells, human HIF-1␣ is subjected to hydroxylation on proline residue 402 and/or 564, a modification that is required for binding of the von Hippel-Lindau tumor suppressor protein, which recruits a ubiquitin-protein ligase that targets HIF-1␣ for degradation (5) . In well-oxygenated cells, asparagine-803 is also hydroxylated, and this modification blocks binding of coactivator proteins p300 and CREB-binding protein (CBP) to the transactivation domain (6) . The prolyl and asparaginyl hydroxylases, PHD2 and FIH-1, use O 2 as a substrate, and their activity is inhibited under hypoxic conditions, leading to increased HIF-1␣ protein stability and transcriptional activation. HIF-1 binds to hypoxia response elements (HREs), which are cis-acting DNA sequences containing the consensus binding site 5Ј-(A/ G)CGTG-3Ј, that are defined by their ability to mediate hypoxiainducible and HIF-1-dependent transcription when inserted into a reporter gene (7) .
Increased HIF-1␣ levels, as determined by immunohistochemical analysis of tumor biopsy sections, are associated with increased patient mortality in many types of human cancer, a finding that is consistent with the contributions of HIF-1 to cancer progression that have been demonstrated in cell culture and animal models (2) . In prostate cancer patients treated with radiotherapy or radical prostatectomy, increased HIF-1␣ levels are associated with reduced time to disease progression (8) . In hepatocellular carcinoma, increased HIF-1␣ levels are associated with venous and lymph node invasion and patient mortality (9) .
Inhibitors of HIF-1 may be useful for cancer therapy; and compounds that inhibit HIF-1␣ synthesis, stability, DNAbinding activity, and transactivation have been identified (2, 10) . Several known chemotherapeutic agents act as HIF-1 inhibitors, and new clinical trials have been initiated in which patient selection and dosing strategies are designed to target HIF-1 (10) . Here, we report that anthracyclines, one of the most potent classes of chemotherapeutic agents in clinical use, inhibit HIF-1 transcriptional activity. We show that inhibition of HIF-1 activity provides a molecular basis for the antiangiogenic properties of anthracyclines. These findings have important implications for refining the use of these drugs to treat human cancer more effectively.
conditions [ Fig. 1A and supporting information (SI) Fig. S1 A] . We screened the entire Johns Hopkins Drug Library, a collection of 3,120 drugs that have been approved by the Food and Drug Administration or have entered phase II clinical trials (11) . The most potent HIF-1 inhibitor identified by this screen was daunorubicin (DNR), which inhibited hypoxia-induced Luc activity by Ͼ99% at a concentration of 10 M. Epirubicin (EPI) and idarubicin (IDA), which are other anthracycline chemotherapeutic agents, were also identified in the screen. A doseresponse study of DNR, EPI, IDA, and doxorubicin (DXR) confirmed that these compounds significantly decreased hypoxia-induced Luc activity at concentrations as low as 0.2 M (Fig. 1 A and Fig. S1 A) . Endogenous HIF-1 target gene expression was also inhibited by anthracyclines: VEGF and GLUT1 mRNA levels in hypoxic cells were significantly decreased by DNR, DXR, EPI, or IDA in a dose-dependent manner ( Fig. 1 A  and Fig. S1B ). Luc activity that was mediated by cotransfection of expression vector encoding HIF-1␣ or HIF-2␣ was also inhibited by DNR or DXR in a dose-dependent manner (Fig.   1B) . These results indicate that the anthracyclines DNR, DXR, EPI, and IDA inhibit HIF-1-mediated transcriptional responses to hypoxia.
Anthracyclines Disrupt Binding of HIF-1 to DNA. To determine the mechanism underlying the effect of anthracyclines on HIF-1 activity, we first examined HIF-1␣ protein levels. O 2 -dependent regulation of HIF-1␣ stability is a major determinant of hypoxia signaling, and several compounds inhibit HIF-1-mediated gene expression by reducing HIF-1␣ levels (2, 10) . To determine whether anthracyclines affect HIF-1␣ levels, immunoblot assays were performed by using lysates of cells that were exposed to hypoxia for 20 h in the presence of DNR, DXR, EPI, or IDA at concentrations ranging from 0 to 10 M. HIF-1␣ protein levels were at the limit of detection in cells exposed to 20% O 2 but were markedly increased by exposure of cells to 1% O 2 (Fig. S2 A) . This induction was observed in the absence or presence of DNR, DXR, EPI, or IDA, indicating that anthracyclines do not block HIF-1␣ accumulation.
To determine whether anthracyclines inhibit transactivation, cells were cotransfected with a Luc reporter gene containing GAL4-binding sites and a vector encoding the GAL4 DNAbinding domain (DBD) alone or fused to HIF-1␣ sequences (12) . In cells expressing GAL-O (GAL4-DBD alone), Luc activity was low and was not induced by hypoxia (Fig. S2B) . Compared with GAL-O, expression of GAL-A (GAL4-DBD fused to HIF-1␣ 531-826 ) or GAL-C (GAL4-DBD/HIF-1␣ 653-826 ) resulted in higher Luc activity at 20% O 2 and a Ͼ6-fold increase in response to hypoxia (Fig. S2B) . Luc activity was not inhibited by exposure of cells to 5 M DNR, DXR, EPI, or IDA. GAL-H (GAL4-DBD/HIF-1␣ 786 -826 ), which lacks the binding site for the asparaginyl hydroxylase FIH-1 and transactivates the reporter in an O 2 -independent manner (12), was also unaffected by anthracycline compounds (Fig. S2B) . These results exclude the possibility that anthracyclines inhibit HIF-1␣ transactivation.
We also tested whether anthracyclines inhibit dimerization of HIF-1␣ and HIF-1␤, which is required for DNA binding and consequent transcriptional responses. A pulldown assay was performed using a purified GST (GST)-HIF-1␤ fusion protein and lysates from HEK293 cells transfected with FLAG epitopetagged HIF-1␣. FLAG-HIF-1␣ was pulled down by GST-HIF-1␤ but not by GST alone, and the interaction was not inhibited in the presence of DNR, DXR, EPI, or IDA (Fig. S2C) . These results indicate that anthracyclines do not inhibit HIF-1 transcriptional activity by blocking dimerization. The other possible mechanism by which anthracyclines might target hypoxia-induced transcription is by blocking the binding of HIF-1 to DNA. To determine whether anthracycline compounds inhibit binding of endogenous HIF-1 to DNA in hypoxic human cells, chromatin-bound HIF-1␣ was immunoprecipitated from HEK293 cells exposed to 1% or 20% O 2 for 20 h in the presence or absence of 1 M DNR, DXR, EPI, or IDA. HIF-1 binding sites from the VEGF and PDK1 genes were specifically amplified by PCR using chromatin immunoprecipitated from control hypoxic cells, indicating hypoxia-induced binding of HIF-1 (Fig. 2) . Treatment of the cells with DNR, DXR, EPI, or IDA eliminated binding of HIF-1 to these DNA sequences. Anthracyclines were recognized as agents that bind to DNA, with optimal binding sites of 5Ј-(A/T)CG-3Ј and 5Ј-(A/ T)GC-3Ј (13, 14) . HIF-1 binds to the sequence 5Ј-(A/ G)CGTG-3Ј (7), which overlaps the optimal binding site for anthracyclines. Treatment of cells with DNR or DXR also blocked hypoxia-induced binding of HIF-2␣ to the VEGF and PDK1 genes ( whether inhibition of HIF-1 DNA-binding activity by anthracyclines contributes to the anticancer properties of these compounds, we examined the effects of DNR and DXR on HIF-1 target gene expression in Hep3B-c1 tumor xenografts. We first confirmed that DNR and DXR had no effect on HIF-1␣ protein levels in cultured Hep3B-c1 cells (Fig. S4A) , whereas hypoxiainduced expression of GLUT1 and VEGF mRNA was significantly inhibited by treatment of the cells with Ն0.2 M DNR or DXR (Fig. S4B) , which was similar to HEK293 cells (Fig. 1) . We next implanted 5 ϫ 10 6 Hep3B-c1 cells, which were stably transfected with the HIF-1-regulated Luc reporter, s.c. in the flank of SCID mice. Tumors were allowed to grow to a volume of Ϸ200 mm 3 , and mice were then randomized into three treatment groups. Before the initiation of treatment (day 27), tumor growth was identical across groups (Fig. 3A) . Analysis of HIF-1-dependent Luc activity by whole-body Xenogen imaging revealed bioluminescence at the tumor site that was similar in all groups (Fig. 3B Upper) . DNR or DXR was injected i.v. on days 28-31 at a dose of 1 mg/kg, which is 5 times lower than the bolus dose of DXR conventionally used to block tumor growth in mice (16) . HIF-1-dependent Luc activity was imaged 4 h after treatment on day 30. The bioluminescence in tumors before and after treatment with vehicle was similar. In contrast, Luc activity was markedly decreased after treatment with either DNR or DXR (Fig. 3B) . There was no significant difference in mean tumor volumes on day 30 (Fig. 3A) , indicating that inhibition of HIF-1 transcriptional activity preceded inhibition of tumor growth, which was first observed on day 31.
Analysis of the tumors 4 h after the last dose on day 31 revealed that HIF-1␣ protein was highly expressed in tumors from mice treated with vehicle, DNR, or DXR (Fig. 3C ). In agreement with inhibition of HIF-1-dependent Luc activity, expression of mRNAs encoded by HIF-1 target genes VEGF, GLUT1, HK1, and HK2 was significantly decreased in tumors after treatment with DNR or DXR compared with vehicle ( Fig.  3D ). Taken together, these results demonstrate that anthracyclines inhibit HIF-1 transcriptional activity in tumors without affecting HIF-1␣ protein levels.
Anthracyclines Inhibit Prostate Tumor Growth and Angiogenesis. The effects of DNR and DXR on HIF-1 transcriptional activity in cultured PC-3 human prostate cancer cells were similar to those in HEK293 and Hep3B-c1 cells because anthracyclines did not affect HIF-1␣ protein levels but blocked hypoxia-induced expression of HIF-1 target genes (Fig. S5) . SCID mice received s.c. injections of 5 ϫ 10 6 PC-3 cells, and tumor xenografts were allowed to grow to a volume of Ϸ100 mm 3 and randomly divided into five treatment groups: vehicle, DNR (0.5 and 1.5 mg/kg), or DXR (0.5 and 1.5 mg/kg). DNR or DXR was injected i.v. from day 17 through day 21. Treatment of mice with DNR or DXR at 0.5 or 1.5 mg/kg per day for 5 days led to a significant inhibition of tumor growth compared with vehicle treatment (Fig. 4A) .
Tumors cannot grow beyond microscopic size without angiogenesis, and the crucial role of HIF-1 in angiogenesis has been well documented (1, 2, 5). Many angiogenic cytokines, including VEGF and stromal-derived factor 1 (SDF1), are encoded by HIF-1 target genes (3, 17) . One of the consequences of VEGF and SDF1 production by hypoxic cancer cells is mobilization into the bloodstream of circulating angiogenic cells (CACs), a term that designates the heterogeneous population of endothelial progenitor cells, mesenchymal stem cells, myeloid cells, and other cells that home to the tumor and promote vascularization. HIF-1 plays a critical role in this process (18) .
To analyze the effect of anthracyclines on CAC levels, mice bearing PC-3 tumor xenografts were treated with DNR or DXR for 5 days (Fig. 4A) , and 4 h after the last dose, peripheral blood was collected for flow cytometric analysis of CACs, as defined by the coexpression of a progenitor cell marker [CD34, CD117 (c-kit), or sca1] and either VEGFR2 or CXCR4, the receptor for VEGF and SDF1, respectively. The number of CACs was increased Ͼ4-fold in SCID mice bearing tumors compared with mice without tumors, and no significant differences were observed between untreated and vehicle-treated tumor-bearing mice (Fig. 4B) . In contrast, anthracycline treatment significantly reduced CACs in tumor-bearing mice to levels observed in mice without tumors.
To investigate the mechanism by which anthracycline treatment blocks CAC mobilization, we analyzed angiogenic cytokine mRNA expression in tumor xenografts. Administration of DNR or DXR inhibited the expression of mRNA encoding VEGF, SDF1, and stem cell factor (SCF), which is the ligand bound by CD117 (Fig. 4C) . Analysis of SDF1 protein levels in peripheral blood by ELISA revealed that compared with non-tumorbearing mice, SDF1 levels were significantly increased in tumorbearing mice treated with vehicle, whereas DXR treatment for 5 days reduced SDF1 in the blood of tumor-bearing mice to levels similar to those observed in non-tumor-bearing mice (Fig. 4D) . This inhibition of HIF-1-mediated angiogenic cytokine expression provides a molecular mechanism by which anthracycline chemotherapy blocks CAC mobilization in tumor-bearing mice (Fig. 4E) . The decreased angiogenic growth factor gene expression and decreased CAC mobilization was associated with a dramatic reduction in tumor vascularization after administration of DNR or DXR for 5 days (Fig. 5) .
Discussion
In this work, we have demonstrated that inhibition of HIF-1 transcriptional activity is a class effect shared by all anthracyclines tested, including DNR, DXR, EPI, and IDA. The anticancer effect of these drugs when administered episodically at the maximum tolerated dose was attributed to their ability to intercalate DNA and induce topoisomerase II-mediated strand breaks (15) . More recently, adriamycin (DXR) has been shown to inhibit tumor xenograft growth through antiangiogenic effects (16, 19) . However, before our study, the mechanism by which anthracycline chemotherapy impairs tumor angiogenesis had not been established. A previous study reported that the anthracycline aclacinomycin B inhibited expression of a HIF-1-dependent reporter gene in Chinese hamster ovary cells, but, in contrast to our results, this study reported that neither DXR nor DNR had an inhibitory effect (20) . DXR was shown to inhibit hypoxia-induced VEGF mRNA expression in cultured ovarian cancer cells, but the mechanism of action was not established (21) . Anthracyclines have been reported to inhibit AP1, GATA4, and SP1 (22) (23) (24) , indicating that they have multiple effects on transcription.
The results of our work demonstrate that anthracyclines block the binding of HIF-1 to DNA in hypoxic human cells, as demonstrated by chromatin immunoprecipitation, whereas these drugs do not affect HIF-1␣ synthesis, stability, dimerization, or transactivation. Administration of DXR or DNR potently inhibited HIF-1 transcriptional activity in human prostate cancer xenografts and potently inhibited tumor growth. These results are consistent with clinical data correlating increased HIF-1␣ levels with prostate cancer progression (8) .
Treatment of mice with DNR or DXR for 5 days inhibited the expression in tumor xenografts of VEGF, SDF1, and SCF mRNAs, which are encoded by HIF-1 target genes (3, 17, 25) . VEGF, SDF1, and SCF are angiogenic cytokines that play key roles in tumor vascularization through the mobilization of CACs bearing the cognate receptors VEGFR2, CXCR4, and CD117, respectively. Treatment with DNR or DXR inhibited tumormediated CAC mobilization. Taken together, our results indicate that inhibition of HIF-1 transcriptional activity by DNR or DXR leads to decreased VEGF, SDF1, and SCF expression, which leads to decreased CAC mobilization, resulting in decreased tumor vascularization and growth.
In addition to establishing a molecular basis for the antiangiogenic effect of anthracycline chemotherapy, our results have important implications for future use of these drugs in clinical oncology. A general principle of targeted therapy is that patient selection is based on the demonstration that increased expression or activity of the target is associated with poor prognosis. Based on this reasoning, patients with HIF-1␣ overexpression demonstrated by immunohistochemistry on biopsy of cancers in which this phenotype is associated with increased mortality, such as prostate and hepatocellular carcinoma (8, 9) , may be particularly good candidates for inclusion of daily DXR or DNR in a treatment regimen. Clinical trials are warranted to test these hypotheses, and additional preclinical studies are needed to investigate the effects of daily anthracycline therapy on other aspects of cancer biology that are regulated by HIF-1, including tumor metabolism, invasion, and metastasis.
Materials and Methods
Cell Culture. HEK293 and Hep3B-c1 cells were maintained in DMEM (Mediatech). PC-3 cells were cultured in RPMI medium 1640 (Invitrogen). Media were supplemented with 10% FCS (Hyclone), 100 units/mL penicillin, and 100 g/mL streptomycin (Invitrogen). Cells were incubated at 37°C in 5% CO 2. For hypoxia treatment, cells were placed in a closed chamber flushed with 1% O 2/5% CO2/94% N2. DNR, DXR, EPI, and IDA (Sigma-Aldrich) were dissolved DMSO for use in cell-based studies.
Screening of Drug Library. Hep3B-c1 cells were established by stable cotransfection of plasmids p2.1 (7) and pSV-Renilla using FuGENE-6 (Roche). Cells were treated with drugs from an established library (11) or vehicle (1% DMSO), exposed to 20% or 1% O 2 for 24 h, lysed, and analyzed for the ratio of firefly to Renilla Luc activity by using the Dual Luciferase assay system (Promega).
Quantitative Real-Time Reverse Transcriptase (qRT) PCR Assay. Total RNA was extracted by using TRIzol reagent (Invitrogen) and treated with DNase (Ambion). A 1-g aliquot of total RNA was reverse-transcribed by using the iScript cDNA synthesis system, and qRT-PCR was performed by using iQ SYBR Green Supermix and iCycler Real-time PCR detection system (Bio-Rad). Primers (Table  S1 ) were designed by using Beacon Designer software (Bio-Rad) and determined to be specific by BLAST and dissociation curve analysis. The expression level of each mRNA was normalized to the expression of 18S rRNA in the same sample.
Immunoblot Assays. Preparation of whole-cell lysates (WCLs) and immunoblot analysis were performed as described in ref. 26 by using antibodies against FLAG (Sigma-Aldrich), HIF-1␣, and ␤-actin (Santa Cruz Biotechnology).
GST Pulldown Assays. GST-HIF1␤11-510 was generated by PCR amplification of the bHLH-PAS domain of HIF-1␤ from cDNA (primers shown in Table S2 ). The PCR product was inserted into pGEX-5X-1 (GE Healthcare). GST fusion proteins were purified as described in ref. 26 . WCLs were prepared from HEK293 cells transfected with FLAG-HIF-1␣ by using lysis buffer [50 mM Tris⅐Cl (pH 7.5), 150 mM NaCl, 0.1% Nonidet P-40, 1 mM DTT, 1 mM Na3VO4, 10 mM NaF, and protease inhibitor mixture]. An 800-g aliquot of WCL and 4 g of GST-HIF-1␤ or GST were incubated in the presence of 5 M DNR, DXR, EPI, or IDA, or vehicle control (1% DMSO), overnight at 4°C. A 30-L aliquot of glutathione-Sepharose 4B beads (GE Healthcare) was added followed by incubation for 3 h at 4°C to capture GST fusion proteins. After washing with lysis buffer, proteins were eluted using Laemmli buffer and subjected to immunoblot assays. (12) by using FuGENE-6 as described above. pSV-Renilla was used as an internal control. After transfection, cells were exposed to 20% or 1% O 2 for 24 h in the presence of 5 M DNR, DXR, EPI, or IDA, then lysed and analyzed for the ratio of firefly to Renilla Luc activity.
GAL4 Reporter
Chromatin Immunoprecipitation Assay. HEK293 cells were treated with 1 M DNR, DXR, EPI, or IDA and exposed to 20% or 1% O 2 for 24 h. Chromatin immunoprecipitation was performed with the ChIP assay kit (Upstate-Cell Signaling Solution) by using rabbit polyclonal anti-HIF-1␣ antibodies and normal rabbit IgG as a negative control (Santa Cruz Biotechnology). VEGF and PDK1 gene sequences were detected by PCR using primers listed in Table S3 .
Xenograft Assays. Male SCID mice were purchased at 5 weeks of age from the National Cancer Institute. DXR, DNR, and saline used for animal studies were purchased from the pharmacy of the Johns Hopkins Hospital. Mice were implanted s.c. with 5 ϫ 10 6 Hep3B-c1 or PC-3 cells suspended in 0.2 mL of DMEM or RPMI medium 1640, respectively. The mice were monitored twice weekly for body weight and tumor volume (V), which was calculated according to the following formula: V ϭ length ϫ width ϫ height ϫ 0.52. When tumor volume reached 200 (Hep3B-c1) or 100 (PC-3) mm 3 , mice were divided randomly into control and treatment groups.
In Vivo Imaging. Mice bearing Hep3B-c1 xenografts received an i.p. injection of 3 mg of D-luciferin firefly (Caliper Life Science) dissolved in 0.2 mL of PBS. They were anesthetized and imaged for Luc activity by using the Xenogen IVIS 200 optical imaging device in the Johns Hopkins Molecular Imaging Center.
Flow Cytometry. Blood samples were collected from tumor-bearing mice after treatment with 0.5 or 1.5 mg/kg of DXR or DNR for 5 days. A 100-L aliquot of anticoagulated peripheral blood was incubated with 1 g of fluorescein isothiocyanate-and phycoerythrin-conjugated monoclonal antibodies against CXCR4 and ScaI, VEGFR2 and CD34, or VEGFR2 and CD117, respectively (BD Biosciences). Red cells were lysed by using 0.8% NH4Cl/10 mM EDTA (Stem Cell Technologies). Cells were collected by centrifugation for 5 min at 400 ϫ g and analyzed by using a FACScan flow cytometer (BD Biosciences) that was equipped with an argon laser emitting at 488 nm. From 100,000 events, the percentage of cells showing dual fluorescence was determined.
Immunohistochemistry. PC-3 xenografts were fixed in 10% formalin, embedded in paraffin, and 5-m sections were prepared, mounted on positively charged slides, hydrated through xylene and graded ethanol, and washed with PBS. Endogenous peroxidase activity was quenched by using 3% H 2 O 2 in methanol, and nonspecific binding was blocked by incubation with blocking solution (BioGenex). CD31 (1:50; BD Pharmingen) or SMA (1:50; Sigma) antibodies were applied for 1 h. The slides were washed with PBS/0.1% Tween 20 and incubated with biotinylated secondary antibody (1:1,000; Vector Laboratories) for 1 h. Antibody was visualized with Vectastain Elite ABC immunoperoxidase system (Vector Laboratories). Sections were counterstained with hematoxylin. The CD31-or SMA-positive area was quantified (40ϫ objective, 20 fields from each slide) by using ImageJ software (National Institutes of Health).
ELISA. Peripheral blood was collected from mice, allowed to clot, and centrifuged at 2,000 ϫ g for 20 min. Serum SDF-1␣ concentration was determined in duplicate for each sample by ELISA (R&D Systems). Optical density was measured at 450 nm and 570 nm (correction) by using an AD340 plate reader (Beckman Coulter). SDF-1␣ concentration was calculated by linear regression from a standard curve.
